Amgen (AMGN) Says Outcomes Study Shows Repatha Decreases LDL-C to Unprecedented Low Levels, Reduces Risk of Cardiovascular Events
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) today announced that the 27,564-patient Repatha® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
